Boehringer Ingelheim announces FDA approval of Stiolto Respimat inhaler for the treatment of COPD.

Visterra announces partnership with A*STAR to develop VIS513, a monoclonal antibody for the treatment of dengue fever.

EMA confirms its recommendation to suspend medicines approved based on GVK Biosciences studies.

The House Energy Committee’s approval of the 21st Century Cures legislation is only a first step, with critics and collaborators alike lining up to comment.

OXY-CAPT brings together properties of plastic and glass containers through the combination of oxygen absorption and cyclic olefin copolymer (COP) high barrier layers.

Merus and Selexis will combine technology platforms to produce colorectal cancer combination therapy.

Medicago's new production facility will make plant-based vaccines and therapeutics.

CVS Health signed a definitive agreement to acquire Omnicare for $12.7 billion to expand its reach to assisted living and long-term care facilities.

The House Energy and Commerce Committee gave unanimous approval to the landmark 21st Century Cures Act reform bill on May 21, 2015.

The new guideline replaces the previous version-CHMP/EWP/240/95 Revision 1.

The Denmark facility will incorporate CMC’s Bioreactor 6Pack configuration in one manufacturing line.

The former New England Compounding Center will pay $200 million to victims and creditors for the 2012 outbreak of meningitis that killed 64.

Symbiosis Pharmaceutical Services is now offering a new bulk lyophilization (freeze drying) service in response to increasing demand in the manufacture of bulk intermediates and APIs by lyophilization.

Janssen pledges $6 million to Rutgers CSOPS for continuous manufacturing research.

The method patent covers the infusion of bendamustine hydrochloride for the treatment of certain blood cancers.

The Critical Path Institute launched a consortium to help develop therapies for newborns.

Emergent gives ProMetic long-term access to its Winnipeg facility.

Alexion will construct a biologics facility in Ireland that is its first outside the US.

The Irish company Endo International announced that it would acquire Par Pharmaceutical for $8.05 billion.

AstraZeneca announces that it will invest $285 million in a new manufacturing facility in Sweden.

UK-based Circassia invests approximately $377 million on Aerocrine and Prosonix, two companies focused on asthma.

CPhI Worldwide announces the 2015 Expert Panel, including 2014 panel veterans and three new members.

Raplixa fibrin sealant, the first approved spray-dried biologic, is a hemostatic agent that helps control bleeding from small blood vessels during surgery.

SAFC’s new ADC wing in St. Louis, MO will feature commercial-scale manufacture of antibody-drug conjugates, and its Carlsbad, CA site will offer enhanced gene-therapy services.

The dinner will be held on Oct. 14, 2015 during CPhI Worldwide, at the Prado Museum in Madrid.

Supply chain consortium establishes a working group to address quality problems in India.

CPhI Istanbul to feature materials, manufacturing, packaging and contract services solutions.

FDA concludes Orkambi demonstrates a clinical benefit over placebo, but questions the magnitude of the improvement.